Who Owns Carboplatin?

Carboplatin exists because of cisplatin. In the 1960s, biophysicist Barnett Rosenberg at Michigan State University discovered that platinum compounds inhibited bacterial cell division, work that led to the development of cisplatin as the first platinum-based chemotherapy drug. The FDA approved cisplatin in December 1978 for testicular cancer, and it proved remarkably effective but difficult to tolerate, causing severe nausea, kidney damage, and nerve toxicity.

Researchers at the Institute of Cancer Research in London, working with Johnson Matthey, screened hundreds of platinum analogs through the late 1970s looking for a compound that kept cisplatin's antitumor activity while cutting its toxicity. Carboplatin emerged as the leading candidate. Bristol-Myers licensed the compound and drove it through clinical development, with much of the pivotal trial work conducted by UK and European cooperative groups.

The FDA approved Paraplatin in March 1989, initially for advanced ovarian cancer. It quickly became the preferred platinum agent for outpatient regimens because patients experienced far less nausea and no routine need for aggressive hydration to protect the kidneys. The trade-off was heavier bone marrow suppression, particularly thrombocytopenia.

Two developments defined the drug's clinical life in the 1990s. First, the Calvert formula introduced dosing based on renal function and target drug exposure (AUC dosing), which remains the standard way carboplatin is prescribed today. Second, combination therapy with paclitaxel became the backbone regimen for ovarian cancer and later for non-small cell lung cancer, a pairing still used daily in infusion centers worldwide.

US patent protection on Paraplatin expired in the mid-2000s, and generic versions flooded the market within a few years. Branded Paraplatin sales collapsed from hundreds of millions of dollars to negligible levels, a standard patent-cliff outcome. Bristol-Myers Squibb eventually stopped promoting the brand as generics took essentially 100 percent of volume.

Carboplatin remains one of the most prescribed chemotherapy agents in the world. It sits on the WHO Model List of Essential Medicines, and its role expanded again in the 2010s and 2020s as a combination partner for immunotherapy regimens in lung cancer, where carboplatin plus pemetrexed or paclitaxel is given with checkpoint inhibitors including BMS's own Opdivo.